pI: 5.0202 |
Length (AA): 448 |
MW (Da): 50462 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | Bloodstream Form. | Siegel TN |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | Procyclic. | Siegel TN |
Siegel TN | Genome-wide analysis of mRNA abundance in two life-cycle stages of Trypanosoma brucei and identification of splicing and polyadenylation sites. |
Ortholog group members (OG5_127685)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT2G30710 | RabGAP/TBC domain-containing protein |
Babesia bovis | BBOV_II002460 | TBC domain containing protein |
Brugia malayi | Bm1_37555 | TBC domain containing protein |
Candida albicans | CaO19.11292 | Gtpase activating protein for Ypt1p |
Candida albicans | CaO19.3811 | Gtpase activating protein for Ypt1p |
Caenorhabditis elegans | CELE_F32B6.8 | Protein TBC-3, isoform B |
Cryptosporidium hominis | Chro.30295 | TBC domain |
Cryptosporidium parvum | cgd3_2560 | TBC1 domain containing protein |
Dictyostelium discoideum | DDB_G0269982 | hypothetical protein |
Drosophila melanogaster | Dmel_CG5745 | CG5745 gene product from transcript CG5745-RA |
Echinococcus granulosus | EgrG_001054300 | TBC1 domain family 2B |
Entamoeba histolytica | EHI_196990 | Rab GTPase activating protein, putative |
Echinococcus multilocularis | EmuJ_001054300 | TBC1 domain family 2B |
Homo sapiens | ENSG00000054611 | TBC1 domain family, member 22A |
Homo sapiens | ENSG00000065491 | TBC1 domain family, member 22B |
Leishmania braziliensis | LbrM.30.1470 | GTPase activating protein, putative |
Leishmania donovani | LdBPK_301410.1 | GTPase activating protein, putative |
Leishmania infantum | LinJ.30.1410 | GTPase activating protein, putative |
Leishmania major | LmjF.30.1350 | GTPase activating protein, putative |
Leishmania mexicana | LmxM.29.1350 | GTPase activating protein, putative |
Loa Loa (eye worm) | LOAG_05272 | TBC domain-containing protein |
Mus musculus | ENSMUSG00000042203 | TBC1 domain family, member 22B |
Mus musculus | ENSMUSG00000051864 | TBC1 domain family, member 22a |
Neospora caninum | NCLIV_014640 | TBC domain-containing protein, putative |
Oryza sativa | 4347577 | Os09g0515800 |
Plasmodium berghei | PBANKA_1361300 | TBC domain protein, putative |
Plasmodium falciparum | PF3D7_1348500 | TBC domain protein, putative |
Plasmodium knowlesi | PKNH_1252400 | TBC domain protein, putative |
Plasmodium vivax | PVX_083320 | TBC domain protein, putative |
Plasmodium yoelii | PY05115 | TBC domain, putative |
Saccharomyces cerevisiae | YOR070C | Gyp1p |
Schistosoma japonicum | Sjp_0216130 | TBC1 domain family member 22B, putative |
Schistosoma mansoni | Smp_022130 | hypothetical protein |
Schmidtea mediterranea | mk4.008868.00 | |
Schmidtea mediterranea | mk4.011578.00 | |
Schmidtea mediterranea | mk4.009193.02 | |
Trypanosoma brucei gambiense | Tbg972.6.2600 | GTPase activating protein, conserved, putative |
Trypanosoma brucei | Tb927.6.2830 | GTPase activating protein, conserved |
Trypanosoma congolense | TcIL3000_0_57880 | GTPase activating protein, conserved |
Trypanosoma cruzi | TcCLB.511753.80 | GTPase activating protein, putative |
Trypanosoma cruzi | TcCLB.511501.50 | GTPase activating protein, putative |
Toxoplasma gondii | TGME49_285730 | TBC domain containing protein |
Theileria parva | TP04_0374 | TBC domain protein, putative |
Trichomonas vaginalis | TVAG_235350 | conserved hypothetical protein |
Trichomonas vaginalis | TVAG_329290 | conserved hypothetical protein |
Trichomonas vaginalis | TVAG_483540 | conserved hypothetical protein |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.6.2830 this record | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.6.2830 this record | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.6.2830 this record | Trypanosoma brucei | significant gain of fitness in procyclic forms | alsford |
Tb927.6.2830 this record | Trypanosoma brucei | significant gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
TGME49_285730 | Toxoplasma gondii | Essentiality uncertain | sidik |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
Affected Entity | Phenotypic quality | Occurs in | Occurs at | Evidence | Observed in | Drugs/Inhibitors |
---|---|---|---|---|---|---|
cell proliferation (GO:0008283) | normal (PATO:0000461) | bloodstream stage trypomastigotes (PLO:0027) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | normal cell proliferation (no significant loss or gain of fitness) in bloodstream forms (stage 6 days). | References: | 21363968 | |
cell proliferation (GO:0008283) | increased (PATO:0000470) | procyclic (PLO:0034) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | increased cell proliferation (significant gain of fitness) in differentiation of procyclic to bloodstream forms . | References: | 21363968 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
1 literature reference was collected for this gene.